Results 181 to 190 of about 12,023 (208)

Reigniting the Flame for Redifferentiation Strategies in Differentiated Thyroid Cancers: Journey of Tyrosine Kinase Inhibitors to Renewed Radioactive-Iodine Avidity. [PDF]

Endocrinol Metab (Seoul)
Oh JM, Zhu L, Ahn BC.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Oncogenic rearrangements of the NTRK1/NGF receptor

Cancer Letters, 2006
The NTRK1 gene encodes the high affinity receptor for Nerve Growth Factor, and its action regulates neural development and differentiation. Deregulation of NTRK1 activity is associated with several human disorders. Loss of function mutations causes the genetic disease congenital insensitivity to pain with anhidrosis (CIPA).
Marco A Pierotti, Angela Greco
exaly   +3 more sources

Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma

Cancer Letters, 2015
Chromosomal rearrangements of the NTRK1 gene, which encodes the high affinity nerve growth factor receptor (tropomyosin related kinase, TRKA), have been observed in several epithelial cancers, such as colon cancer, papillary thyroid carcinoma or non small cell lung cancer.
Laurent, Créancier, Isabelle, Vandenberghe, Bruno, Gomes, Caroline, Dejean, Jean-Christophe, Blanchet, Julie, Meilleroux, Rosine, Guimbaud, Janick, Selves, Anna, Kruczynski   +8 more
exaly   +3 more sources

RET and NTRK1 proto‐oncogenes in human diseases

Journal of Cellular Physiology, 2003
AbstractRET and NTRK1 are receptor tyrosine kinase (RTK) proteins which play a role in the development and maturation of specific component of the nervous system. Their alterations have been associated to several human diseases, including some forms of cancer and developmental abnormalities.
Luisella, Alberti, Cristiana, Carniti, Claudia, Miranda, Emanuela, Roccato, Marco A, Pierotti   +4 more
openaire   +2 more sources

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer

Cancer Research
Abstract Treatment of non–small cell lung cancer (NSCLC) has drastically changed in recent years owing to the robust anticancer effects of immune checkpoint inhibitors (ICI). However, only 20% of the patients with NSCLC benefit from ICIs, highlighting the need to uncover the mechanisms mediating resistance.
Margaret R. Smith, Caroline B. Dixon, Yuezhu Wang, Yin Liu, Ralph D’Agostino, Jimmy Ruiz, George Oliver, Lance D. Miller, Umit Topaloglu, Michael D. Chan, Michael Farris, Jing Su, Kathryn F. Mileham, Dawen Zhao, Wencheng Li, Tammy Sexton, Thomas Lycan, Karen M. Haas, Jason M. Grayson, Fei Xing   +19 more
openaire   +2 more sources

EPS15–NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma

Journal of Cancer Research and Clinical Oncology, 2020
Shengzhuang Yang, Lijian Li, Dongsheng Chen, Mingzhe Xiao, Lei Xian   +4 more
openaire   +1 more source

Genomic organization of the human NTRK1 gene.

Oncogene, 1997
The NTRK1 gene encodes one of the receptors for the Nerve Growth Factors and it is located at 1q21-22. Rearrangements of NTRK1 are frequently detected in human papillary thyroid carcinoma and lead to the formation of chimeric oncogenes, similarly to what observed for the other neurotrophin receptor RET. In addition, the two receptor genes are target of
A, Greco, R, Villa, M A, Pierotti
openaire   +1 more source

A novel NTRK1 aberrant splicing variant

a novel variant c.850+5G>A in NTRK1, which broadened the and enriched the NTRK1 mutation ...
openaire   +1 more source

NTRK1 Spitz melanoma presenting clinically as an angioma

International Journal of Dermatology, 2023
Audelia, Arasheben, Mansee, Desai, Michael P, Lee, Justin, Love, Conroy, Chow, Justin, Kerstetter, Ashley, Elsensohn   +6 more
openaire   +2 more sources